Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AG06466 in Fibromyalgia
NCT04974359Phase 1Terminated
- Sponsor
- Lundbeck
- Start
- Jun 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in fibromyalgia (FM) comparing Lu AG06466 with Placebo (2 arms). Primary endpoints: Blood Oxygene Level Dependent (BOLD) Response in the Evoked-Pain Test at Day 22, Change in Resting State fMRI (rsfMRI) Functional Connectivity at Day 22 and 1 more. Started Jun 2021; status: terminated.
02
Drugs
ABX-1431
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT04974359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04974359.